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 Summary
 Background: Previous case-control studies have suggested that the absence of a swallow-tail appearance in 
the substantia nigra on high-resolution SWI, representing nigrosome-1, has high accuracy to 
identify Parkinson’s disease (PD). The first goal of our study was to evaluate nigrosome-1 ex vivo 
using optimized high-resolution susceptibility sensitive MRI. Our second goal was to evaluate its 
diagnostic value in vivo using a clinical 3T SWI sequence to differentiate between PD and atypical 
parkinsonism (AP) in a cohort of patients with early-stage parkinsonism.
 Material/Methods: Case-control pilot study to evaluate nigrosome-1 ex vivo (2 PD, 2 controls), using high-resolution 
susceptibility sensitive sequences at 11.7 T MRI. Next, evaluation of nigrosome-1 in vivo using a 
clinical 3 T SWI sequence in a prospective cohort of 60 patients with early-stage parkinsonism (39 
PD, 21 AP). Moreover, 12 control subjects were scanned.
  The bilateral substantia nigra was evaluated by two neuroradiologists for the presence, absence or 
indecisive presence of nigrosome-1. The discriminative power was evaluated by Receiver-Operating 
Characteristic.
 Results: We identified nigrosome-1 in ex vivo control subjects. Nigrosome-1 was not identified in the ex vivo 
PD cases. In our prospective clinical cohort study, the AUC for the swallow-tail sign to discriminate 
between PD and AP was 0.56 (0.41–0.71) for reader 1 and 0.68 (0.55–0.82) for reader 2.
 Conclusions: The diagnostic accuracy of the swallow-tail sign was marginal to discriminate between PD and AP 
using our clinical 3 T SWI sequence.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder 
with incidence increasing with age. The diagnosis of PD 
is made on clinical grounds, based on classic motor symp-
toms including bradykinesia, rest tremor or rigidity [1,2]. 
Conventional brain MRI lacks a diagnostic marker spe-
cific for PD [3]. Previously, studies have been published 
with promising results regarding T 1 and T 2 signal inten-
sity changes of the substantia nigra (SN) in PD [4,5], which 
could not be reproduced in follow-up studies. In the diag-
nostic work-up of parkinsonism, brain MRI is therefore 
mainly used to exclude other, more rare causes of parkin-
sonism such as vascular damage or hydrocephalus. Also, 
abnormalities on brain MRI could support the diagnosis 
of a neurodegenerative disorder other than PD, usually 
referred to as atypical parkinsonism (AP). These include 
multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), dementia with Lewy bodies (DLB) and cortico-
basal syndrome (CBS).
New MRI techniques such as diffusion tensor imaging (DTI) 
and magnetization transfer imaging (MTI) may have the 
potential to provide a new diagnostic marker specific for 
PD [6], but clinical application of these techniques is lim-
ited because study results are not consistent and validat-
ed diagnostic criteria are generally lacking [6,7]. This also 
accounts for quantitative measures of iron content of the 
SN in PD, demonstrated as increased susceptibility on T 2* 
or Susceptibility Weighted Imaging (SWI) sequences [8–10].
In recent in vivo and postmortem studies using high-res-
olution susceptibility sensitive MR imaging techniques 
(7 T but also 3 T MRI), a new diagnostic marker has been 
reported with high accuracy to identify PD [11–13]. A sub-
region in the ventro-lateral part of the substantia nigra 
lacking susceptibility and bordered by two lines of sus-
ceptibility, resembling a swallow-tail (Figure 1), repre-
sents nigrosome-1 and is identified in healthy controls. The 
absence of this swallow-tail configuration has been report-
ed in PD, with observed good discrimination between PD 
and control subjects (reported accuracy 91–96%) [14]. It is 
not known whether the absence of the swallow-tail sign on 
SWI could discriminate PD from AP.
The first goal of our pilot study was to evaluate the swal-
low-tail appearance in the substantia nigra ex vivo, using 
optimized high-resolution susceptibility sensitive MRI 
sequences. Our second goal was to evaluate the diagnostic 
value of the swallow-tail sign to differentiate between PD 
and AP in a cohort of patients with early-stage parkinson-
ism using a clinical 3 T SWI sequence.
Material and Methods
Ex vivo case-control study (11.7 T MRI)
Formalin-fixed postmortem midbrain samples of 2 patients 
with histopathologically confirmed PD (76 y/o male and 81 
y/o female) and 2 controls (76 and 84 y/o females without 
a neurodegenerative disorder) were collected. Slices of the 
midbrain including the lower part of the substantia nigra 
were rehydrated with phosphate buffered saline for one 
week to reduce fixation-induced T2 shortening. A uni-
lateral part of the midbrain samples (measuring approxi-
mately 10×10×5 mm), was placed in a syringe filled with 
Galden D40 perfluoropolyether (Solvay Solexis, New York). 
The samples were stored at room temperature for 72 hours 
prior to scanning and air bubbles were removed. This 
method is in accordance with a previous ex vivo MRI study 
of our group [15].
Imaging was performed on an 11.7-T BioSpec Avance III 
small animal MRI system (Bruker BioSpin, Ettlingen, 
Germany) equipped with an actively shielded gradient set 
of 600 mT/m and operated by the ParaVision 5.1 software 
platform. A circular polarized volume resonator was used 
for signal transmission, and an actively decoupled mouse 
brain quadrature surface coil with integrated combiner and 
preamplifier (Bruker BioSpin) for signal reception. After 
standard adjustments, 2D and 3D gradient echo sequences 
were acquired. Details of the scanning protocol are provid-
ed in Table 1.
The images were visually inspected by two neuroradi-
ologists (FJAM and BG) for the presence of a swallow-tail 
appearance in the substantia nigra pars compacta, in order 
to identify nigrosome-1.
Clinical cohort and case-control study (clinical 3T SWI)
A prospective observational study of 60 patients present-
ing with early stage parkinsonism, part of a larger clini-
cal cohort study, was performed. Those patients were 
prospectively recruited as part of a larger clinical cohort 
study. The work described was carried out in accordance 
with The Code of Ethics of the World Medical Association 
(Declaration of Helsinki) for experiments involving 
humans. The medical ethics committee of our hospital 
Figure 1.  Schematic representation of nigrosome-1 on SWI 
(asterisks), a subregion in the ventrolateral substantia nigra 
pars compacta lacking susceptibility bordered by two lines 
of susceptibility resembling a swallow tail. R – red nucleus, 
M – mammillary body.
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(CMO Arnhem-Nijmegen) approved the study and all par-
ticipants gave written informed consent prior to inclusion. 
Patients were recruited at our outpatient movement disor-
der clinic in the period 2010–2012.
Study inclusion criteria were clinical signs and symptoms 
of parkinsonism (hypokinetic-rigid syndrome) with uncer-
tain clinical diagnosis and disease duration of less than 3 
years. Exclusion criteria were age under 18 years, prior 
brain surgery, presence of another neurodegenerative dis-
order and unstable co-morbidity.
After a mean clinical follow-up of 24.6 (±12.4) months, ‘sil-
ver standard’ diagnoses could be made by two experienced 
clinicians (AR, RE): 39 patients were diagnosed with PD 
and 21 patients with AP (13 MSA-P, 3 PSP, 3 DLB, 1 vas-
cular parkinsonism, 1 CBS). Those diagnoses were made 
according to international diagnostic criteria [16–21], based 
on neurological signs that developed during the course of 
the disease (as identified during repeat neurological exams), 
rate of disease progression and treatment response. In 
addition, 12 controls were included. Demographic criteria 
of the study groups are summarized in Table 2. In compari-
son to PD, disease severity and severity of motor symptoms 
were higher for AP (p<0.05).
At baseline of this study, all patients had a 3-T brain MRI 
scan (Magnetom Trio, Siemens, Erlangen, Germany), which 
included a clinical SWI sequence with a high in-plane reso-
lution but 3-mm slice thickness (0.63×0.63×3 mm voxels). 
Details of the scanning protocol are provided in Table 1.
These SWI sequences were visually evaluated by two neu-
roradiologists (FJAM and SS), blinded to clinical infor-
mation and diagnoses. The bilateral substantia nigra 
was scored for the unambiguous presence, unambiguous 
absence, or indecisive presence of the swallow-tail sign. 
Unilateral absence of the swallow-tail sign was considered 
indicative of PD irrespective of the other side, as the onset 
of PD can be asymmetrical.
Cohen’s kappa co-efficient was used to evaluate intra- 
and inter-rater variability. Agreement was graded as: 
kappa <0.20, poor agreement; 0.21–0.4, fair agreement; 
0.41–0.60, moderate agreement; 0.61–0.80, good agree-
ment; >0.80, excellent agreement. One reader (FJAM) 
scored all MRI studies twice with a two-week interval in 
order to evaluate the intra-rater variability.
The discriminative power of the swallow-tail appear-
ance was evaluated for both readers with the Receiver-
Operating-Characteristic (ROC).
Results
Ex vivo case-control study (11.7 T MRI)
Nigrosome-1 was identified by a swallow-tail appearance 
in the ventrolateral substantia nigra pars compacta on the 
MR images of the two control samples, while nigrosome-1 
was not identified in the two PD samples (Figure 2).
Study/MR 
field strength Sequence TR/TE
Flip 
angle ° Matrix size Voxel (mm)
No. of 
averages
Acquisition
time
Ex vivo/11.7 T
2D MGE* 1248/5 12 512×512 0.079×0.079×0.64 2 16 min
3D MGE* with 11 
echos 57/3.4–53.4 30 256×256 0.112×0.112×0.112 – 47 min
In vivo SWI 3 mm 
sliced/3 T
3D gradient echo 
SWI 29/20 15 384×384 0.63×0.63×x3 1 4 min, 42 sec
Table 1. Details of the MRI scanning protocols used.
* MGE – multi gradient echo.
PD (n=39) AP (n=21) Controls (n=12)
Mean age (yrs)  61.5 (9.1)  64.8 (7.7)  71.4 (7.4)
Gender (M: F) 24: 15 9: 12 8: 4
Disease duration (months)  21.6 (11.9)  28.4 (11.1) –
MMSE  28.5 (1.6)  28.2 (1.5) –
H&Y  1.7 (0.65)*  2.4 (0.61)* –
UPDRS-III  32.4 (12)*  45.7 (12.8)* –
Table 2. Demographic data of the prospective study group.
PD – Parkinson’s disease; AP – atypical parkinsonism; MMSE – mini-mental state examination; H&Y – Hoehn and Yahr staging scale; 
UPDRS-III – Unified Parkinson Disease Rating Scale – III. * Student’s t-test p-value <0.05.
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Clinical cohort and case-control study (clinical 3 T SWI)
Table 3 demonstrates the distribution of nigrosome-1 as 
identified by both readers in PD, AP and controls. Inter-
rater variability proved to be fair (kappa 0.35). Intra-rater 
variability proved to be moderate (kappa 0.44). For read-
er 2, nigrosome-1 was identified in the majority of PD 
patients (56%), while this was the case in a minority of PD 
patients for reader 1 (23%).
The ability of the swallow-tail sign to discriminate 
between PD and controls resulted in an AUC of 0.72 
(0.58–0.87) for reader 1 and 0.58 (0.39–0.77) for reader 
2. For the discrimination between PD and AP, the AUC 
was 0.56 (0.41–0.71) for reader 1 and 0.68 (0.55–0.82) for 
 reader 2.
Figure 2.  Ex vivo midbrain samples scanned with 
a multi-gradient echo sequence on 
a 11.7-T MRI scanner. A swallow tail 
appearance of nigrosome-1 is identified 
in the lower part of the substantia nigra 
pars compacta (encircled) in two control 
subjects (A, C). Nigrosome-1 could not be 
identified in the two samples diagnosed 
with Parkinson’s disease (B, D). R – red 
nucleus.
A
C
B
D
Nigrosome-1
absent 
Nigrosome-1
present 
Nigrosome-1
indecisive 
Reader 1
PD (n=39)  23 (59%)  9 (23%)  7 (18%)
AP (n=21)  14 (67%)  6 (29%)  1 (5%)
Controls (n=12)  1 (8%)  8 (67%)  3 (25%)
Reader 2
PD (n=39)  13 (33%)  22 (56%)  4 (10%)
AP (n=21)  14 (67%)  7 (33%)  0 (0%)
Controls (n=12)  6 (50%)  5 (42%)  1 (8%)
Table 3. The absence, presence and indecisive presence of nigrosome-1 in Parkinson’s disease, atypical parkinsonism and controls.
PD – Parkinson’s disease; AP – atypical parkinsonism.
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Discussion
A compartmental organization of the substantia nigra, 
consisting of the nigral matrix and nigrosomes, was first 
described based on the immunohistochemical staining of 
calbindin in striatonigral afferent fibers [22]. It was reported 
that the largest of the nigrosomes called nigrosome-1, locat-
ed in the ventro-lateral substantia nigra, was most affected 
in PD exhibiting the maximum depletion of dopaminergic 
cells [23]. Based on the results of previous case-control stud-
ies [11–14], the swallow-tail sign seems to be a promising 
new diagnostic MRI marker in the diagnostic work-up of 
parkinsonism. In contrast to quantitative MRI techniques, 
this possible new diagnostic marker can be easily imple-
mented in everyday clinical practice because there is no 
requirement for complicated post-processing prior to visual 
assessment. Using an 11.7-T MRI scanner, we were able to 
identify the swallow-tail appearance of nigrosome-1 in the 
substantia nigra pars compacta in ex vivo midbrain samples 
of controls. In two midbrain samples with histopathologi-
cally confirmed PD, this structure was absent. Yet, no stud-
ies have been published evaluating nigrosome-1 in AP, and 
evaluating its diagnostic value in discriminating PD from AP.
In our prospective observational cohort study, the diag-
nostic accuracy of the swallow-tail sign to differentiate 
between PD and AP was marginal, with limited intra- and 
inter-rater agreement. This also accounts for the differen-
tiation between PD and controls, with a diagnostic per-
formance clearly lower than the case-control studies pub-
lished previously. A likely explanation for this discrepancy 
is that the 3-mm slices of our clinical SWI protocol were 
too thick to reliably visualize nigrosome-1, despite its high 
in-plane resolution. This explanation is supported by the 
fact that a swallow-tail configuration in the substantia 
nigra was missing in a significant part of the control sub-
jects on this sequence. The minimal required spatial resolu-
tion of SWI to reliably identify nigrosome-1 has not been 
reported, though an optimized 3D high-resolution SWI is 
probably crucial with increased confidence at higher mag-
netic field strengths. In a very recent case-control study 
comparing 7 T and 3 T for the evaluation of nigrosome-1 
[23], the confidence in revealing the inner structure of the 
substantia nigra on 3 T was inferior to that of 7 T as dem-
onstrated by lower intra- and inter-observer agreement at 
3 T. Also, the diagnostic accuracy to identify PD proved to 
be slightly lower for 3 T (86%) in comparison to 7 T MRI 
(96%). Increased T 2* contrast and magnetic susceptibil-
ity effects of paramagnetic substances at higher magnet-
ic fields is the explanation the authors consider the most 
likely for the superior imaging performance of 7T, rather 
than a higher spatial resolution which only differed slightly 
between 3 T and 7 T [24].
Furthermore, it can be debated whether a swallow-tail 
configuration identified on our relatively thick-sliced SWI 
sequence actually represents nigrosome-1 in the inner 
structure of the substantia nigra, or would be a reflection 
of the closely related substantia nigra and subthalamic 
nucleus. This bears the risk of a false-positively identified 
nigrosome-1.
Another discrepancy with previous studies is that a swal-
low-tail configuration in the substantia nigra was fre-
quently seen in our prospective cohort of patients diag-
nosed with PD. Our PD patients were probably scanned 
earlier in the course of the disease (mean disease duration 
of 21.6 months) than the case-control studies published 
previously (which included patients with disease dura-
tion of up to 10 years) [12,14,24]. The absence of nigro-
some-1 in the substantia nigra in PD on SWI is probably 
not explained by predominant degeneration or volume loss, 
but is most likely explained by pathologically increased 
iron accumulation with increased susceptibility on SWI as 
a result [14]. However, in previous studies increase of the 
iron concentrations of the substantia nigra did not seem to 
Figure 3.  Axial 3 T SWI images of the midbrain (0.63×0.63×3-mm voxel) demonstrating a swallow tail configuration in the substantia nigra in a 
patient diagnosed with dementia with Lewy bodies (A), and its absence in a patient diagnosed with vascular parkinsonism (B).
A B
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be related to the disease duration in PD, while it was corre-
lated with the severity of motor symptoms [25,26]. Another 
possible explanation for the absence of nigrosome-1 in PD 
is decreased neuromelanin content of the substantia nigra 
with decreased iron storage capacity leading to more free 
iron with paramagnetic properties [27]. It needs to be 
determined whether the absence of nigrosome-1 on SWI in 
PD is related to disease duration and whether it correlates 
with loss of presynaptic dopamine transporters, as demon-
strated by nuclear scan techniques. In case the absence of 
nigrosome-1 on SWI was not related to disease duration, 
it could prove to be a useful diagnostic MRI marker in the 
work-up of early-stage parkinsonism. It needs to be deter-
mined whether it is PD-specific and not valid for atypical 
parkinsonism, as absence of the swallow-tail sign was also 
noted in AP in our clinical cohort (Figure 3).
There are some limitations to our study. Our in vivo and 
ex vivo case-control studies included only a few subjects. 
Because case-control studies with a larger amount of sub-
jects have been published recently, we only aimed to repro-
duce the identification of the healthy nigrosome-1, and 
its absence in PD. A limitation of our clinical prospective 
observational cohort is that we do not have any post-mor-
tem confirmation of the diagnoses, and therefore we can-
not fully rule out misdiagnosis. Well-designed prospective 
clinical cohort studies are warranted for assessing the diag-
nostic accuracy of the swallow-tail sign in early-stage par-
kinsonism. Conducting such a study is challenging because 
obtaining histopathological confirmation for larger study 
populations is practically impossible. Although high rates 
of misdiagnosis have been reported on for the clinical 
diagnosis, pathological studies show high accuracy levels 
(>90%) for the clinical diagnosis when the diagnosis was 
made by a movement disorder specialist after a minimal 
follow-up of 2 years [28].
Conclusions
The diagnostic accuracy of the swallow-tail sign was mar-
ginal to discriminate between PD and AP using our clinical 
3 T SWI sequence with high in-plane resolution but 3-mm 
slice thickness. The diagnostic value of the swallow-tail 
sign in the work-up of early-stage parkinsonism using an 
optimized high-resolution SWI sequence needs to be deter-
mined in future well-designed prospective clinical cohort 
studies.
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